Source: Becker's Spine Review

Spiderwort: Spiderwort secures $13.2M to advance spinal cord scaffold

Spiderwort, a startup developing cellulose-based tissue scaffolding to treat acute spinal cord injuries, has secured $13.2 million through a series A financing round, the company said July 12.

Read full article »

Spiderwort's Competitors | Spiderwort's News | Spiderwort's Financials

Followers on Owler

Est. Annual Revenue

$100K-5.0M

Est. Employees

25-100

Co-Founder & CEO

Charles M. Cuerrier

CEO Approval Rating

86/100

Spiderwort is a Canada-based biotechnology company that develops and commercializes novel cellulose biomaterials for the treatment of soft tissue replacement.